Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial

NCT06636981 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06636981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06636981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
November 4, 2024
Completion date
September 30, 2029
Enrollment
129 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer (tnbc)